医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Cellix Bio Pharma Completes the Acquisition of Avaca Pharma

2020年08月05日 AM07:30
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company. Avaca Pharma services include discovery, formulation development, regulatory support, and product development activities.

The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations. Combined with Cellix Bio’s established small molecule discovery and drug development capabilities, this expansion uniquely positions Cellix Bio Pharma as a leading provider of integrated R&D services across large and small molecule platforms a base for further expansion.

With a vision of an innovative approach of execution, exceptional customer service, and focus on providing value, Cellix Bio Pharma is delighted to offer expanded leading-edge service solutions.

Avaca Pharma Research and Development Centre (RDC) at IDA Pashamylaram, Hyderabad, has a total high-quality, compliant space of 6000 sq. ft. in a 1.2-acre location, of which Formulation R&D occupies 3000 sq. ft. and Analytical Operations, 3000 sq. ft., with provisions for expansion.

Avaca Pharma Commercial Operations Centre (COC) is located between Hyderabad and Vijayawada, Andhra Pradesh. The new planned construction will host commercial manufacturing, packaging, analytical, and warehousing facilities within the 14 acres environmentally friendly campus. The facility will have a total built-up cGMP space of 126,685 sq.ft. meeting regulatory compliance standards.

About Cellix Bio Pharma

Cellix Bio Pharma is a wholly-owned subsidiary of Cellix Bio. Cellix Bio Pharma focuses on the development of pharmaceutical formulations. Our long experience in developing pharmaceutical products enables us to find the most cost-effective and safest way to clinical testing of your product. We are in Hyderabad, in one of the top science hubs in India. The team members have been working with drug discovery, development, drug delivery technologies in different surroundings. They have strong product development and regulatory filings pipeline in oral, parenteral, inhalation, ocular, and topical products at various stages. More information on Cellix Bio Pharma: www.cellixbiopharma.com

About Avaca Pharma

Avaca Pharma is a new-gen pharmaceutical development and commercialization organization with a vision to innovate for better health. Rooted in integrity, technical acumen, customer service, and reliability. Our organizational goal is to thrive for the best patient outcome. Avaca Pharma is vested in bringing quality pharmaceutical products with a patient-centric approach. More information on Avaca Pharma: www.avacapharma.com

About Cellix Bio

Cellix Bio is an innovative biopharmaceutical company focused on developing innovative technologies that have the potential to make a significant medical and commercial impact with value-driven clinical outcomes. Cellix Bio works closely with the scientific community, universities, and research institutions to advance and build the value of Synergix AITM technology, develop the most promising intellectual property, and create value for its stakeholders and investors. Cellix Bio has a robust pipeline of new medicines addressing unmet medical needs across diverse therapeutic areas, including neurology, ophthalmic, dermatology, oncology, inflammation, and metabolic diseases. More information on Cellix Bio: www.cellixbio.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804006078/en/

CONTACT

Mahesh Kandula

email: kmahesh@avacapharma.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 患者安全運動財団が2030年までに予防可能な患者死亡ゼロを達成するとの使命を支える新コミットメントモデルを発表
  • 患者安全运动基金会推出新的承诺模式,以支持到2030年实现可预防的患者死亡人数为零的使命
  • アジア太平洋地域での成長計画を促進すべくHumanigen Australia Proprietary Limitedを設立
  • MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ
  • COVAXX Announces $2.8 Billion in Advance Purchase Commitments to Deliver More Than 140 Million Vaccine Doses to Emerging Countries